雲頂新耀宣佈於5月2日起正式從股份簡稱中移除“B”
中國上海—2025年4月28日—雲頂新耀(1952.HK)是一家專注於創新藥研發、臨牀開發、製造和商業化的生物製藥公司,今日宣佈,公司已滿足香港聯交所上市規則第8.05(3)條的市值/收益要求,其股份簡稱中的“B”標記於2025年4月22日獲得批準移除,相關變更將自2025年5月2日起正式生效。雲頂新耀作爲滬深港通下港股通標的,股份簡稱“B”標記的成功移除,標誌着公司在市值和收入等方面已達到主板上市企業要求。自2020年10月在香港聯交所上市以來,公司加快推進授權引進與自主研發相結合的“雙輪驅動”戰略,專注高價值“藍海”領域,致力於研發同類首創或同類最佳的創新療法。目前,公司已擁有三款商業化產品,實現了業績的高速增長。同時,公司積極推進自研及全球權益產品差異化管線佈局,加速新一代共價可逆BTK抑制劑EVER001和AI+mRNA技術平臺的創新研發,釋放全球合作潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.